Published in:
01-04-2011 | Article
Glucose tolerance, insulin sensitivity and insulin release in European non-diabetic carriers of a polymorphism upstream of CDKN2A and CDKN2B
Authors:
M. L. Hribal, I. Presta, T. Procopio, M. A. Marini, A. Stančáková, J. Kuusisto, F. Andreozzi, A. Hammarstedt, P.-A. Jansson, N. Grarup, T. Hansen, M. Walker, N. Stefan, A. Fritsche, H. U. Häring, O. Pedersen, U. Smith, M. Laakso, G. Sesti, on behalf of the EUGENE2 Consortium
Published in:
Diabetologia
|
Issue 4/2011
Login to get access
Abstract
Aims/hypothesis
The aim of this study was to investigate the association of the rs10811661 polymorphism near the CDKN2B/CDKN2A genes with glucose tolerance, insulin sensitivity and insulin release in three samples of white people with European ancestry.
Methods
Sample 1 comprised 845 non-diabetic offspring of type 2 diabetes patients recruited in five European centres participating in the EUGENE2 study. Samples 2 and 3 comprised, respectively, 864 and 524 Italian non-diabetic participants. All individuals underwent an OGTT. Screening for the rs10811661 polymorphism was performed using a TaqMan allelic discrimination assay.
Results
The rs10811661 polymorphism did not show a significant association with age, BMI and insulin sensitivity. Participants carrying the TT genotype showed a significant reduction in insulin release, measured by an OGTT-derived index, compared with carriers of the C allele, in the three samples. When these results were pooled with those of three published studies, and meta-analysed with a random-effects model, the T allele was significantly associated with reduced insulin secretion (−35.09 [95% CI 14.68–55.52], p = 0.0008 for CC+CT vs TT; and −29.45 [95% CI 9.51–49.38], p = 0.0038, for the additive model). In addition, in our three samples, participants carrying the TT genotype exhibited an increased risk for impaired glucose tolerance (IGT) compared with carriers of the C allele (OR 1.55 [95% CI 1.20–1.95] for the meta-analysis of the three samples).
Conclusions/interpretation
Our data, together with the meta-analysis of previously published studies, show that the rs10811661 polymorphism is associated with impaired insulin release and IGT, suggesting that this variant may contribute to type 2 diabetes by affecting beta cell function.